Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

EBOS (ASX:EBO) share price on hold after monster $1.16 billion deal

The New Zealand based EBOS Group Ltd (ASX: EBO) share price is on hold after announcing the acquisition of LifeHealthcare from Pacific Equity Partners for $1.16 billion.

The business will raise up to $742 million to fund the purchase, hence why the share price won’t be moving today.

EBOS is the largest wholesaler and distributor of healthcare, medical, animal food and pharmaceutical products across Australasia.

EBO share price

Source: Rask Media EBO 5-year share price
Source: Rask Media EBO 5-year share price

EBOS expands into South-east Asia

LifeHealthcare is a large distributor of third party medical devices across spine, neurosurgery and orthopaedics.

It has over 120 relationships with equipment manufactures, with an average tenure of the top 10 suppliers of 13 years.

Acquiring the business will significantly accelerate EBOS’s exposure to medical devices and provide a gateway into South East Asia.

Source: EBO LifeHealthcare Investor Presentation
Source: EBO LifeHealthcare Investor Presentation

LifeHealthcare is expected to generate $110-$114 million in EBITDA for 2022, which will add 30% to EBOS earnings before synergies.

The acquisition is EBOS’s 20th over the past ten years, as the company positions itself as a dominant wholesaler in the Asia-Pacific region.

Raising details

The deal for LifeHealthcare will be funded through a combination of cash, debt and equity:

  • $100 million non-underwritten retail offer to existing shareholders
  • $642 million fully-underwritten placement to eligible institutional investors
  • $540 million in new loan facilities
  • $23 million in new EBOS shares issued to LifeHealthcare management

Major shareholder Sybos Holdings, which owns 18.9% of EBOS, has agreed to take up its full entitlement.

The new shares will be issued at a 5.5% discount to the EBOS last closing price and represent 11.9% of the existing EBOS shares on issue.

Strong start to FY22

In addition to announcing the purchase of LifeHealthcare, EBOS provided a trading update for the first four months of FY22.

Revenue is up 10.6% across the group led by 14.3% growth in Animal Care.

This has translated into earnings before interest and tax (EBIT) growth of 13.1% and a net profit after tax (NPAT) increase of 14.2%.

Dividends for FY22 are expected to be between 60-80% of NPAT.

Final thoughts

PEP originally purchased LifeHealthcare in 2018 for $179 million. Now it’s selling it to EBOS for $1.16 billion.

Without including any capital injected and acquisitions joined onto LifeHealthcare, that’s a 59% annual return on its purchase.

Regardless of the earnings and synergies EBOS extracts, it looks like PEP has done very well out of this deal.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Lachlan does not have a financial or commercial interest in any of the companies or funds mentioned.
Skip to content